These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 17523245)

  • 1. Frequent methamphetamine use, primary NNRTI resistance.
    Carter M
    IAPAC Mon; 2007 Jan; 13(1):12. PubMed ID: 17523245
    [No Abstract]   [Full Text] [Related]  

  • 2. Frequent methamphetamine use is associated with primary non-nucleoside reverse transcriptase inhibitor resistance.
    Colfax GN; Vittinghoff E; Grant R; Lum P; Spotts G; Hecht FM
    AIDS; 2007 Jan; 21(2):239-41. PubMed ID: 17197817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.
    Tambuyzer L; Azijn H; Rimsky LT; Vingerhoets J; Lecocq P; Kraus G; Picchio G; de Béthune MP
    Antivir Ther; 2009; 14(1):103-9. PubMed ID: 19320243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
    Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG
    AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonnucleotide reverse-transcriptase inhibitors and treatment interruption.
    DiNubile MJ
    Clin Infect Dis; 2008 Dec; 47(12):1602; author reply 1603. PubMed ID: 19025367
    [No Abstract]   [Full Text] [Related]  

  • 6. Transmission of drug-resistant HIV-1 is stabilizing in Europe.
    Vercauteren J; Wensing AM; van de Vijver DA; Albert J; Balotta C; Hamouda O; Kücherer C; Struck D; Schmit JC; Asjö B; Bruckova M; Camacho RJ; Clotet B; Coughlan S; Grossman Z; Horban A; Korn K; Kostrikis L; Nielsen C; Paraskevis D; Poljak M; Puchhammer-Stöckl E; Riva C; Ruiz L; Salminen M; Schuurman R; Sonnerborg A; Stanekova D; Stanojevic M; Vandamme AM; Boucher CA
    J Infect Dis; 2009 Nov; 200(10):1503-8. PubMed ID: 19835478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term randomized proof-of-principle trial of TMC278 in patients with HIV type-1 who have previously failed antiretroviral therapy.
    Arastéh K; Rieger A; Yeni P; Pozniak A; Boogaerts G; van Heeswijk R; de Béthune MP; Peeters M; Woodfall B
    Antivir Ther; 2009; 14(5):713-22. PubMed ID: 19704175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of HIV-1 reverse transcriptase.
    Ilina T; Parniak MA
    Adv Pharmacol; 2008; 56():121-67. PubMed ID: 18086411
    [No Abstract]   [Full Text] [Related]  

  • 9. Editorial comment: a plethora or options in multidrug-resistant HIV-1 infection.
    Katzenstein DA
    AIDS Read; 2008 Sep; 18(9):478-9. PubMed ID: 18828232
    [No Abstract]   [Full Text] [Related]  

  • 10. Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase.
    Ren J; Stammers DK
    Virus Res; 2008 Jun; 134(1-2):157-70. PubMed ID: 18313784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretroviral rounds. Resistance: what you don't know--can it hurt you?
    Gathe JC; Elion R
    AIDS Clin Care; 2008 Jun; 20(6):51-2. PubMed ID: 18661634
    [No Abstract]   [Full Text] [Related]  

  • 12. Drugs for HIV infection.
    Medical Letter Inc
    Treat Guidel Med Lett; 2006 Oct; 4(50):67-76. PubMed ID: 16985490
    [No Abstract]   [Full Text] [Related]  

  • 13. HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen.
    Sungkanuparph S; Kiertiburanakul S; Apisarnthanarak A; Malathum K; Sathapatayavongs B
    Int J STD AIDS; 2007 Dec; 18(12):832-4. PubMed ID: 18073016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transmission of drug-resistant HIV-1 in Europe remains limited to single classes.
    SPREAD programme
    AIDS; 2008 Mar; 22(5):625-35. PubMed ID: 18317004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV variants of low frequency may have a big impact.
    Laurence J
    AIDS Read; 2007 Jun; 17(6):300-1. PubMed ID: 17632935
    [No Abstract]   [Full Text] [Related]  

  • 16. Recent highlights in clinical AIDS research.
    Laurence J
    AIDS Read; 2008 Feb; 18(2):64-6. PubMed ID: 18330032
    [No Abstract]   [Full Text] [Related]  

  • 17. Revisiting the concept of a genetic barrier to resistance.
    Rusconi S
    J HIV Ther; 2006 Dec; 11(4):81-3. PubMed ID: 17578211
    [No Abstract]   [Full Text] [Related]  

  • 18. Understanding transmitted HIV resistance through the experience in the USA.
    Taiwo B
    Int J Infect Dis; 2009 Sep; 13(5):552-9. PubMed ID: 19136289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the substitution of one nucleoside analogue by one non-nucleoside reverse transcriptase inhibitor over mitochondrial DNA levels.
    De Felipe B; Blanco A; Soriano-Sarabia N; Muñoz-Fernández MA; Genebat M; Vallejo A; Leal M
    Infection; 2008 Jun; 36(3):266-70. PubMed ID: 18463785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1-resistant strains during 8-week on 8-week off intermittent therapy and their effect on CD4+ T-cell counts and antiviral response.
    Izopet J; Marchou B; Charreau I; Sauné K; Tangre P; Molina JM; Aboulker JP;
    Antivir Ther; 2008; 13(4):537-45. PubMed ID: 18672532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.